Pill Identifier App

Generic Jalyn Availability

Jalyn is a brand name of dutasteride/tamsulosin, approved by the FDA in the following formulation(s):

JALYN (dutasteride; tamsulosin hydrochloride - capsule; oral)

  • Manufacturer: GLAXOSMITHKLINE
    Approval date: June 14, 2010
    Strength(s): 0.5MG;0.4MG [RLD]

Has a generic version of Jalyn been approved?

No. There is currently no therapeutically equivalent version of Jalyn available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Jalyn. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Androstenone derivative
    Patent 5,565,467
    Issued: October 15, 1996
    Inventor(s): Batchelor; Kenneth W. & Frye; Stephen V. & Dorsey, Jr.; George F. & Mook, Jr.; Robert A.
    Assignee(s): Glaxo Wellcome Inc.
    The present invention relates to the compound of formula (I), ##STR1## also known as 17.beta.-N-(2,5-bis(Trifluoromethyl))phenylcarbamoyl-4-aza-5.alpha.-andros t-1-en-3-one, solvates thereof, its preparation, intermediates used in its preparation, pharmaceutical formulations thereof and its use in the treatment of androgen responsive and mediated diseases.
    Patent expiration dates:
    • November 20, 2015
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Androstenone derivative
    Patent 5,846,976
    Issued: December 8, 1998
    Inventor(s): Batchelor; Kenneth William & Frye; Stephen Vernon & Dorsey, Jr.; George F. & Mook, Jr.; Robert A.
    Assignee(s): Glaxo Wellcome Inc.
    The present invention relates to the compound of formula (I), ##STR1## also known as 17.beta.-N-(2,5-bis(Trifluoromethyl))phenylcarbamoyl-4-aza-5.alpha.-andros t-1-en-3-one, solvates thereof, its preparation, intermediates used in its preparation, pharmaceutical formulations thereof and its use in the treatment of androgen responsive and mediated diseases.
    Patent expiration dates:
    • September 17, 2013
      ✓ 
      Patent use: METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
  • Androstenones
    Patent 5,998,427
    Issued: December 7, 1999
    Inventor(s): Batchelor; Kenneth William & Frye; Stephen Vernon
    Assignee(s): Glaxo Wellcome Inc.
    The present invention relates to compounds of formula (I), wherein carbons 1 and 2 are joined by either a single or a double bond; R.sup.1 is hydrogen or methyl; R.sup.2 is hydrogen or methyl; R.sup.3 is (B) wherein X, R.sup.6, R.sup.7 and R.sup.8 are various groups, and pharmaceutically acceptable solvates thereof and their use in the treatment of androgen responsive and mediated diseases. ##STR1##
    Patent expiration dates:
    • September 17, 2013
      ✓ 
      Patent use: METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY ADMININSTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA
      ✓ 
      Drug substance
      ✓ 
      Drug product

See also...

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Advertisement
Close

Recommended

(web4)